Laquinimod

From Ganfyd

Jump to: navigation, search

Contents

Introduction

Immuno-modulating drug under investigation in multiple sclerosis and moderate-to-severe Crohn's disease. European approval has been delayed due to concerns about animal data showing risk of cancer after long-term exposure and teratogenicity. Although in MS, laquinimod slows worsening of disability, its effect on relapses is modest.

Clinical Use

Indications

Administration

Oral Initial dose ranging studies suggest 0.6mg/day for significant surrogate response in multiple sclerosis.

Clinical Issues

  • Hepatic enzyme dearrangement reported

Contra-indications

Cautions and Interactions

Side effects

Special advice

Pharmacology

Believed to act on specific T cells through a shift of Th1 cells to the Th2/Th3 phenotype altering cytokine balance in favour of cytokines IL-4, IL-10 and TGF-beta[1]. Is a a quinoline-3-carboxamide.

References

Personal tools